<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02616705</url>
  </required_header>
  <id_info>
    <org_study_id>15-004819</org_study_id>
    <nct_id>NCT02616705</nct_id>
  </id_info>
  <brief_title>Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis</brief_title>
  <official_title>Bile Usefulness for Detecting IgG4-related Sclerosing Cholangitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mayo Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Nagoya University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mayo Clinic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immunoglobulin G4-related disease (IgG4-RD) is an uncommon inflammatory disorder that may
      affect multiple organ systems, including the biliary tree. IgG4-sclerosing cholangitis
      (IgG4-SC) can be difficult to distinguish from primary sclerosing cholangitis (PSC) or
      cholangiocarcinoma (CCA). The investigators aim to evaluate the sensitivity and specificity
      of bile for the diagnosis of IgG4-SC. Bile samples of patients with biliary strictures of
      various causes, including IgG4-SC, PSC, and CCA, will be collected during clinical
      cholangiography procedures. IgG4 will be measured in bile specimens and bile IgG4
      concentrations compared between IgG4-SC, PSC, CCA, and other types of biliary strictures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will recruit cases from Mayo Clinic Rochester and Japanese institutions such as
      Nagoya City University Hospital, Nagoya Daini Red Cross Hospital, and Kurashiki Central
      hospital. Participants will be individuals who will receive endoscopic retrograde
      cholangiography (ERC), endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) or
      percutaneous transhepatic cholangiography (PTC). Bile samples collected from the target cases
      will be assayed for IgG4 concentration.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Ability of bile IgG4 concentration to distinguish between IgG4-SC, PSC, and CCA.</measure>
    <time_frame>2 year</time_frame>
    <description>Bile concentration of IgG4 will be measured in cases and controls, and the groups will be compared using appropriate statistical methods</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Correlation between bile and serum IgG4 concentrations.</measure>
    <time_frame>2 years</time_frame>
    <description>The relationship between Bile and serum IgG4 concentrations will be assessed for case and controls, using appropriate statistical methods</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>IgG4-related Sclerosing Cholangitis</condition>
  <condition>IgG4-related Disease</condition>
  <arm_group>
    <arm_group_label>IgG4-related sclerosing cholangitis</arm_group_label>
    <description>Patients with IgG4-related sclerosing cholangitis (also called IgG4 associated cholangitis, IgG4 related cholangitis, or biliary IgG4-related disease)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Controls</arm_group_label>
    <description>cholangiocarcinoma, PSC, and other patients with biliary strictures</description>
  </arm_group>
  <biospec_retention>None Retained</biospec_retention>
  <biospec_descr>
    <textblock>
      Bile
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Cases with biliary stricture(s) of any cause
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The presence of a biliary stricture

          -  18 years and older

          -  Consented to IRB 707-03

        Exclusion Criteria:

          -  Younger than 18 years of age

          -  Unable to collect a bile sample

          -  Abnormal postsurgical anatomy preventing collection of a bile sample
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Topazian, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mark D. Topazian, M.D.</last_name>
    <phone>507-26-6931</phone>
    <email>Topazian.Mark@mayo.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katsuyuki Miyabe, M.D., Ph.D.</last_name>
    <phone>507-538-4877</phone>
    <email>miyabe.katsuyuki@mayo.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark D. Topazian, M.D.</last_name>
      <phone>507-266-6931</phone>
      <email>Topazian.Mark@mayo.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nagoya City Universty Graduate School of Medical Sciences</name>
      <address>
        <city>Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Itaru Naito, MD, PhD</last_name>
      <phone>81-52-553-8211</phone>
      <email>inaito@mad.nagoya-cu.ac.jp</email>
    </contact>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2015</study_first_posted>
  <last_update_submitted>July 27, 2017</last_update_submitted>
  <last_update_submitted_qc>July 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 31, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mayo Clinic</investigator_affiliation>
    <investigator_full_name>Mark Topazian</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangitis</mesh_term>
    <mesh_term>Cholangitis, Sclerosing</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunoglobulin G</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Data sharing could be arranged and will require IRB approval</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

